Abstract
Evidence suggests that there may be racial differences in risk factors associated with the development of Alzheimer’s disease and related dementias (ADRD). We used whole genome sequencing analysis and identified a novel combination of three pathogenic variants in the heterozygous state (UNC93A: rs7739897 and WDR27: rs61740334; rs3800544) in a Peruvian family with a strong clinical history of ADRD. Notably, the combination of these variants was present in two generations of affected individuals but absent in healthy members within the family. In silico and in vitro studies have provided insights into the pathogenicity of these variants. These studies predict the loss of function of the mutant UNC93A and WDR27 proteins which induced dramatic changes in the global transcriptomic signature of brain cells, including neurons, astrocytes, and especially pericytes and vascular smooth muscle cells, and thus indicating that the combination of these three variants may affect the neurovascular unit. In addition, key known molecular pathways associated with ADRD were enriched in brain cells with low levels of UNC93A and WDR27. Our findings have thus identified a genetic risk factor for familial ADRD in a Peruvian family with an Amerindian ancestral background.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was funded by Consejo Nacional de Ciencia, Tecnologia e Innovacion Tecnologica de Peru (grant N◦ 024-2019-Fondecyt-BM-INC.INV). Dr. Lino Cardenas was supported by the MGH Physician-Scientist Development Award and the Ruth L. Kirschstein National Research Service Award (5T32HL007208-43) and the Physician-Scientist Development Award (PSDA-MGH).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Ethics Committee of research of the EsSalud Hospital (CIEI) of Arequipa-Peru.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
In this version, we have added table 1 (PCR and sequencing primers)
Data Availability
All data produced in the present study are available upon reasonable request to the authors
